DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Effects of Thyroid Hormone Withdrawal on Metabolic Parameters During Radioactive Iodine Therapy in Thyroid Cancer

Information source: Konkuk University Medical Center
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypothyroidism

Phase: N/A

Status: Recruiting

Sponsored by: Konkuk University Medical Center

Official(s) and/or principal investigator(s):
Suk Kyeong Kim, MD, PhD, Principal Investigator, Affiliation: Konkuk University Medical Center

Overall contact:
Suk Kyeong Kim, MD, PhD, Phone: 82-2-2030-7531, Email: 20120137@kuh.ac.kr


1. The incidence of differentiated thyroid cancer is increasing in Korea. A significant number of them experience severe hypothyroidism in preparation for radioactive iodine (RAI) therapy after total thyroidectomy. 2. Because the function of thyroid hormone is closely linked with lipid and glucose metabolism, overt hypothyroidism after thyroid hormone withdrawal during RAI therapy may induce the changes of metabolic parameters. 3. We investigate the effects of thyroid hormone withdrawal on metabolic and cardiovascular parameters during radioactive iodine therapy in differentiated thyroid cancer.

Clinical Details

Official title: Effects of Thyroid Hormone Withdrawal on Metabolic and Cardiovascular Parameters During Radioactive Iodine Therapy in Differentiated Thyroid Cancer

Study design: Observational Model: Case-Only, Time Perspective: Prospective

Primary outcome: Changes of metabolic parameters

Secondary outcome: Changes of bone turnover markers

Detailed description: 1. Study design measurement of various parameters during hypothyroid state (before 1 month, the day and after 1 month of RAI therapy) 2. Measurements 1. Measurement of metabolic and cardiovascular parameters

- glucose profiles : HbA1c, fasting glucose level

- lipid profiles : free fatty acid, total, LDL-, HDL-, cholesterol,


- adipocytokines : retinol binding protein(RBP)

- 4, leptin, resistin, adiponectin

- markers of endothelial and cardiac function : high-sensitivity C-reactive

protein(hsCRP), homocystein, B-type natriuretic peptide(BNP)

- bone turnover markers : CTX, bone ALP

2. Scoring of symptoms and signs of hypothyroidism (Zulewski score)

- symptoms

- physical signs


Minimum age: 18 Years. Maximum age: 80 Years. Gender(s): Both.


Inclusion Criteria:

- radioiodine therapy after total thyroidectomy in differentiated thyroid cancer

- age over 18

Exclusion Criteria:

- kidney failure, liver failure, heart failure

- infection

- inflammation

- autoimmune disease

- other chronic disease

Locations and Contacts

Suk Kyeong Kim, MD, PhD, Phone: 82-2-2030-7531, Email: 20120137@kuh.ac.kr

Konkuk University Medical Center, Seoul 143-729, Korea, Republic of; Recruiting
Jee Hyun An, Phone: 82-10-9089-4655, Email: jeehyunan@gmail.com
Suk Kyoung Kim, MD, PhD, Principal Investigator
Jee Hyun An, MD, PhD, Sub-Investigator
Ki Ho Song, MD, PhD, Sub-Investigator
Dong Lim Kim, MD, PhD, Sub-Investigator
Additional Information

Starting date: July 2012
Last updated: December 6, 2012

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017